News
More than half of biotech and pharma job seekers have been looking for their next opportunity for six months or longer, and more than a quarter have searched for over a year, according to a BioSpace LinkedIn poll. Job seekers share their frustrations.
FEATURED STORIES
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.
From Eli Lilly’s David Ricks to Pfizer’s Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
FDA veteran Peter Marks will now shape the future of Eli Lilly’s vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total.
THE LATEST
Four biotech companies are holding Research-and-Development Day events to present and discuss their pipelines. Here’s a look.
The new R&D facility is a product of its new licensing deal with BridgeBio Pharma and will operate under Helsinn Therapeutics.
Shares of Enochian Biosciences plunged more than 36% after the Justice Department announced company cofounder Serhat Gumrukçu was arrested in a sordid 2018 murder-for-hire scheme.
A recent study published in Nature Medicine found that people who were vaccinated had a slightly decreased risk of getting Long COVID six months after their initial diagnosis.
Flagship Pioneering introduced ProFound Therapeutics, a new company that leverages previously undiscovered human proteins to develop treatments for many diseases.
Invectys is one of only a few companies investigating HLA-G, a natural immune checkpoint inhibitor, for solid tumors.
At the start of Takeda’s fiscal year on April 1, Ramona Sequeira and Julie Kim stepped into new positions on the company’s executive leadership team and became role models for women.
When the two new sites are up and running, Eli Lilly predicted the project will create up to 500 new jobs - with the expectation of four indirect jobs for each full-time position, based on industry data.
Germany’s CureVac is partnering with Belgium’s myNEO to identify specific cancer antigens in order to develop novel mRNA immunotherapies for cancer vaccines.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.